Domainex has announced a collaboration on drug discovery programmes with the Breakthrough Breast Cancer Research Centre and the Institute of Cancer Research.
The programme hopes to identify and develop inhibitors of two recently validated breast cancer targets, tankyrase and IKK-epsilon.
The collaboration will bring together the Breakthrough Research Centre's expertise in the genetics, biochemistry and cell biology of breast cancer and Domainex's capability to discover innovative drugs using its Leadbuilder hit-finding platform technology and experienced medicinal chemistry team.
The objective of the collaboration is to bring forward inhibitors of both targets to the proof of concept stage in breast cancer models and then to partner the programmes with larger organisations for clinical development.
The Breakthrough Breast Cancer Centre will enable the collaboration to gain a greater understanding of the role of these two targets in breast cancer as well as access to a number of systems for the study of biochemistry and cell biology of inhibitors.
